Immediate Treatment of Anaphylaxis
Administer intramuscular epinephrine 0.3-0.5 mg (adults) or 0.01 mg/kg (children, maximum 0.3-0.5 mg) into the mid-outer thigh immediately upon recognition of anaphylaxis—this is the single most critical intervention that saves lives. 1, 2
First-Line Treatment: Epinephrine Administration
Epinephrine is the only appropriate first-line medication for anaphylaxis with no absolute contraindications. 3, 2 When in doubt about whether a reaction constitutes anaphylaxis, it is better to administer epinephrine than to delay. 3
Dosing and Route
- Adults and adolescents ≥50 kg: 0.3-0.5 mg intramuscular (1:1000 concentration) 4, 2, 5
- Children <50 kg: 0.01 mg/kg intramuscular (maximum 0.3 mg for prepubertal children, 0.5 mg for larger children) 1, 2, 6
- Injection site: Mid-outer aspect of the thigh (vastus lateralis muscle)—this provides faster absorption and higher peak plasma levels compared to subcutaneous or arm injection 1, 4, 2
- The injection can be given through clothing, but avoid seams, pockets, or other obstructions 7
Repeat Dosing
- Administer a second dose 5-15 minutes after the first if symptoms persist or worsen 1, 7, 6
- Between 7-18% of patients require more than one dose of epinephrine 1, 6
- Repeat doses every 5-15 minutes as needed until symptoms resolve or emergency medical services arrive 4, 6
- If the patient requires three or more intramuscular doses or develops refractory hypotension, consider intravenous epinephrine (50-100 mcg boluses of 1:10,000 concentration or continuous infusion at 5-15 mcg/min) 6
Immediate Concurrent Actions
Patient Positioning
- Place the patient supine (flat on back) with lower extremities elevated 2, 8
- If respiratory distress or vomiting is present, position for comfort 1, 2
- Never allow the patient to stand, walk, or run—this can precipitate sudden cardiovascular collapse and death 2, 8
Activate Emergency Medical Services
- Call 911 or activate emergency response immediately 1, 3, 2
- Approximately 500-1000 people die annually in the United States from anaphylaxis, and patients may require advanced interventions including intubation, intravenous fluids, and vasopressors 1
Adjunctive Treatments (Only AFTER Epinephrine)
These are secondary interventions that should never delay epinephrine administration:
- Supplemental oxygen for patients with respiratory symptoms 2
- Intravenous fluid resuscitation with large volumes (crystalloids or colloids) for hypotension or incomplete response to epinephrine 3, 2
- Albuterol nebulizer for persistent bronchospasm 2
- H1 antihistamines (e.g., diphenhydramine) and H2 antihistamines (e.g., ranitidine) may provide symptomatic relief but are not life-saving 3
- Corticosteroids may help prevent biphasic reactions but have no role in acute management 3
Critical Pitfalls to Avoid
- Delayed epinephrine administration is the most common factor in anaphylaxis fatalities 6, 9, 8
- Do not substitute antihistamines or corticosteroids for epinephrine—these medications do not prevent or reverse airway obstruction or cardiovascular collapse 3
- Avoid subcutaneous administration (slower onset) or intravenous bolus in non-critical care settings (higher risk of adverse effects) 4, 9
- Accidental injection into a finger can cause vasoconstriction and necrosis—inject only into the thigh 7
- Do not delay treatment to obtain intravenous access or wait for help to arrive 2
Post-Treatment Management
Observation and Transfer
- All patients must be transferred to an emergency department, preferably by emergency medical services 7, 2
- Minimum observation period is 4-6 hours after successful treatment 2, 6
- Patients requiring multiple epinephrine doses, those with severe initial presentations, or those with unknown triggers require extended observation due to higher risk of biphasic reactions (recurrence hours later) 6
Discharge Planning
- Prescribe two epinephrine autoinjectors with hands-on training for proper use 2
- Provide a written anaphylaxis emergency action plan 2
- Refer to an allergist for trigger identification and long-term management 2
- Instruct patients to wear medical identification (e.g., MedicAlert jewelry) 3
High-Risk Populations
Patients at increased risk for severe or fatal anaphylaxis include:
- Adolescents and young adults 2
- Those with coexisting asthma 2, 8
- Previous history of anaphylaxis 2
- Peanut or tree nut allergies 2, 8
- Delayed epinephrine use in prior reactions 8
These patients require heightened vigilance and must carry epinephrine autoinjectors at all times. 2